RECRUITING

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Talk to us

Conditions

Clinical Stage I Esophageal Adenocarcinoma AJCC v8Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage I Esophageal Adenocarcinoma AJCC v8Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Thoracic Esophagus Squamous Cell Carcinoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.

Official Title

Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer

Quick Facts

Study Start:2019-03-15
Study Completion:2031-12-21
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03801876

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * PRIOR TO STEP 1 REGISTRATION:
  2. * Histologically proven diagnosis of adenocarcinoma or squamous cell carcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II)
  3. * Stage I-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition based on the following diagnostic workup:
  4. * History/physical examination
  5. * Whole-body fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) with or without (+/-) contrast (preferred) or chest/abdominal (include pelvic if clinically indicated) CT with contrast
  6. * For patients who DID NOT receive induction chemotherapy, scan must occur within 30 days prior to Step 1 registration
  7. * For patients who DID receive induction chemotherapy, scan must occur:
  8. * Within 30 days after final induction chemotherapy dose; OR
  9. * Within 30 days prior to Step 1 registration
  10. * Note: Patients who had prior endoscopic mucosal resection (EMR) with a diagnosis of AJCC stage I-IVA, excluding T4b, esophageal cancer are eligible
  11. * Surgical consultation to determine whether or not the patient is a candidate for resection after completion of chemoradiation
  12. * Induction chemotherapy for the current malignancy prior to concurrent chemoradiation allowed if last dose is no more than 90 days and no less than 10 days prior to Step 1 registration. Only FOLFOX will be allowed as the induction chemotherapy regimen.
  13. * Zubrod performance status 0, 1, or 2
  14. * Absolute neutrophil count (ANC) (within 30 days prior to Step 1 registration)
  15. * For patients who DID NOT receive induction chemotherapy: ANC \>= 1,500 cells/mm\^3
  16. * For patients who DID receive induction chemotherapy: ANC \>= 1,000 cells/mm\^3
  17. * Platelets (within 30 days prior to Step 1 registration)
  18. * For patients who DID NOT receive induction chemotherapy: Platelets \>= 100,000/uL
  19. * For patients who DID receive induction chemotherapy: Platelets \>= 75,000/uL
  20. * Hemoglobin \>= 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb \>= 8.0 g/dl is acceptable) (within 30 days prior to Step 1 registration)
  21. * Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or Creatinine clearance \> 40 mL/min estimated by Cockcroft-Gault formula (within 30 days prior to Step 1 registration)
  22. * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (within 30 days prior to Step 1 registration)
  23. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN (within 30 days prior to Step 1 registration)
  24. * Negative pregnancy test (serum or urine) within 14 days prior to Step 1 registration for women of child bearing potential
  25. * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
  1. * Cervical esophageal cancers arisen from 15-18 cm from the incisors
  2. * Patients with T4b disease according to the AJCC 8th edition
  3. * Definitive clinical or radiologic evidence of metastatic disease
  4. * Any active malignancy within 2 years of study registration that may alter the course of esophageal cancer treatment
  5. * Prior thoracic radiotherapy that would result in overlap of radiation therapy fields
  6. * Severe, active co-morbidity defined as follows:
  7. * Active uncontrolled infection requiring IV antibiotics at the time of Step 1 registration
  8. * Uncontrolled symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia not controlled by any device or medication at the time of Step 1 registration
  9. * Myocardial infarction within 3 months prior to Step 1 registration
  10. * Pregnant and/or nursing females
  11. * Human immunodeficiency virus (HIV) positive with CD4 count \< 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count \>= 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive
  12. * PRIOR TO STEP 2 REGISTRATION:
  13. * Unable to obtain confirmation of payment coverage (insurance or other) for either possible radiation treatment

Contacts and Locations

Principal Investigator

Steven Lin
PRINCIPAL_INVESTIGATOR
NRG Oncology

Study Locations (Sites)

Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054
United States
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146
United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442
United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
United States
Miami Cancer Institute
Miami, Florida, 33176
United States
Orlando Health Cancer Institute
Orlando, Florida, 32806
United States
Emory Proton Therapy Center
Atlanta, Georgia, 30308
United States
Emory University Hospital Midtown
Atlanta, Georgia, 30308
United States
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
United States
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342
United States
Alton Memorial Hospital
Alton, Illinois, 62002
United States
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, 60115
United States
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
United States
Memorial Hospital East
Shiloh, Illinois, 62269
United States
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, 60555
United States
Maryland Proton Treatment Center
Baltimore, Maryland, 21201
United States
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
United States
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
United States
McLaren Cancer Institute-Bay City
Bay City, Michigan, 48706
United States
Corewell Health Dearborn Hospital
Dearborn, Michigan, 48124
United States
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
United States
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334
United States
McLaren Cancer Institute-Flint
Flint, Michigan, 48532
United States
Karmanos Cancer Institute at McLaren Greater Lansing
Lansing, Michigan, 48910
United States
McLaren Cancer Institute-Lapeer Region
Lapeer, Michigan, 48446
United States
McLaren Cancer Institute-Owosso
Owosso, Michigan, 48867
United States
Corewell Health William Beaumont University Hospital
Royal Oak, Michigan, 48073
United States
Corewell Health Beaumont Troy Hospital
Troy, Michigan, 48085
United States
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota, 56007
United States
Mercy Hospital
Coon Rapids, Minnesota, 55433
United States
Unity Hospital
Fridley, Minnesota, 55432
United States
Mayo Clinic Health Systems-Mankato
Mankato, Minnesota, 56001
United States
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
United States
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
United States
Mayo Clinic Radiation Therapy-Northfield
Northfield, Minnesota, 55057
United States
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States
Ridgeview Medical Center
Waconia, Minnesota, 55387
United States
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141
United States
Washington University School of Medicine
Saint Louis, Missouri, 63110
United States
Siteman Cancer Center-South County
Saint Louis, Missouri, 63129
United States
Siteman Cancer Center at Christian Hospital
Saint Louis, Missouri, 63136
United States
Mercy Hospital Saint Louis
Saint Louis, Missouri, 63141
United States
Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri, 63376
United States
Mercy Hospital Springfield
Springfield, Missouri, 65804
United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
United States
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
United States
Memorial Sloan Kettering Commack
Commack, New York, 11725
United States
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
United States
New York Proton Center
New York, New York, 10035
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
United States
UH Seidman Cancer Center at UH Avon Health Center
Avon, Ohio, 44011
United States
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122
United States
Geauga Hospital
Chardon, Ohio, 44024
United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219
United States
Case Western Reserve University
Cleveland, Ohio, 44106
United States
Mercy Cancer Center-Elyria
Elyria, Ohio, 44035
United States
UH Seidman Cancer Center at Landerbrook Health Center
Mayfield Heights, Ohio, 44124
United States
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, 44060
United States
UH Seidman Cancer Center at Southwest General Hospital
Middleburg Heights, Ohio, 44130
United States
University Hospitals Parma Medical Center
Parma, Ohio, 44129
United States
University Hospitals Portage Medical Center
Ravenna, Ohio, 44266
United States
UH Seidman Cancer Center at Firelands Regional Medical Center
Sandusky, Ohio, 44870
United States
University Hospitals Sharon Health Center
Wadsworth, Ohio, 44281
United States
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069
United States
UH Seidman Cancer Center at Saint John Medical Center
Westlake, Ohio, 44145
United States
UHHS-Westlake Medical Center
Westlake, Ohio, 44145
United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
United States
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104
United States
Thompson Proton Center
Knoxville, Tennessee, 37909
United States
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
United States
Thompson Cancer Survival Center - West
Knoxville, Tennessee, 37932
United States
Thompson Oncology Group-Maryville
Maryville, Tennessee, 37804
United States
Thompson Oncology Group-Oak Ridge
Oak Ridge, Tennessee, 37830
United States
MD Anderson in The Woodlands
Conroe, Texas, 77384
United States
M D Anderson Cancer Center
Houston, Texas, 77030
United States
MD Anderson West Houston
Houston, Texas, 77079
United States
MD Anderson League City
League City, Texas, 77573
United States
MD Anderson in Sugar Land
Sugar Land, Texas, 77478
United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
United States
Inova Alexandria Hospital
Alexandria, Virginia, 22304
United States
Inova Schar Cancer Institute
Fairfax, Virginia, 22031
United States
Inova Fair Oaks Hospital
Fairfax, Virginia, 22033
United States
Inova Loudoun Hospital
Leesburg, Virginia, 20176
United States
University of Washington Medical Center - Montlake
Seattle, Washington, 98195
United States
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, 54701
United States

Collaborators and Investigators

Sponsor: NRG Oncology

  • Steven Lin, PRINCIPAL_INVESTIGATOR, NRG Oncology

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-03-15
Study Completion Date2031-12-21

Study Record Updates

Study Start Date2019-03-15
Study Completion Date2031-12-21

Terms related to this study

Additional Relevant MeSH Terms

  • Clinical Stage I Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage I Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage II Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Thoracic Esophagus Squamous Cell Carcinoma